European Commission grants final approval to Novo Nordisk 7.2mg Wegovy dose

The company states: “The European Commission has approved a new 7.2 mg once-weekly maintenance dose of Wegovy(R) (semaglutide injection) for adults living with obesity. This gives doctors another option to help adults who need more weight loss after being on the 2.4 mg dose. The approval is based on a positive opinion from the European Medicines Agency’s scientific committee on 12 December 2025. The approval means that doctors in the EU may now prescribe the 7.2 mg dosage as three 2.4 mg injections, to be taken in one sitting, still once a week. Novo Nordisk (NVO) has applied for approval of a 7.2 mg single-dose pen in the EU, and if approved, it could be available this year. This means that in the European Union, adults with obesity may now step directly from Wegovy(R) 2.4 mg (for at least four weeks) up to 7.2 mg if they need greater weight loss while preserving muscle function. Wegovy 7.2 mg is already approved and available in the UK, and regulatory applications are pending with the US Food and Drug Administration and several other countries.”